Idiosyncratic reactions and metabolism of sulfur-containing drugs
- 7 March 2012
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 8 (4) , 467-485
Abstract
Introduction: Idiosyncratic drug reactions (IDRs) that involve the formation of toxic metabolites followed by covalent binding to cellular proteins often go undiscovered until after post-marketing. The goal of this article is to review the current status of IDRs, potential mechanisms and the challenges associated with predicting drug toxicity. Areas covered: The authors review the metabolic pathways of five select classes of sulfur-containing drugs (captopril, troglitazone, tienilic acid, zileuton, methimazole and sudoxicam) suggesting that bioactivation plays a crucial role in the occurrence of IDRs. The reader will gain further awareness that the sulfur atom can propagate as the bioactivation site for the formation of reactive and conceivably toxic metabolites. As such, it is the body's capacity to detoxify these drug products that may determine whether IDRs occur. Expert opinion: Incomplete understanding of mechanisms culminating in IDR occurrence represents a monumental impediment toward their abrogation. Moreover, current technology utilized to predict their manifestation (including structure–toxicity relationships) is not infallible and thus, development of novel tools and strategies is indispensible. In an attempt to streamline clinical development and drug approval processes, consortiums have been instated under the US FDA Critical Path Initiative. Collectively, these parameters along with the availability of validated biomarkers and new/updated regulatory guidance could positively influence the outcome of drug toxicity profiles and direct future drug development.Keywords
This publication has 105 references indexed in Scilit:
- Risk assessment and mitigation strategies for reactive metabolites in drug discovery and developmentChemico-Biological Interactions, 2011
- Characterization of Glutathione Conjugates of Duloxetine by Mass Spectrometry and Evaluation ofin SilicoApproaches to Rationalize the Site of Conjugation for Thiophene Containing DrugsChemical Research in Toxicology, 2010
- Synergistic drug–cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicityToxicology and Applied Pharmacology, 2009
- Phenotypic characterization of idiosyncratic drug‐induced liver injuryHepatology, 2009
- In VitroMetabolism and Covalent Binding of Enol-Carboxamide Derivatives and Anti-Inflammatory Agents Sudoxicam and Meloxicam: Insights into the Hepatotoxicity of SudoxicamChemical Research in Toxicology, 2008
- The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profileExpert Opinion on Drug Safety, 2007
- Clinical Pattern of Zileuton-Associated Liver InjuryDrug Safety, 2007
- Role of animal models in the study of drug-induced hypersensitivity reactionsThe AAPS Journal, 2005
- Adverse hepatic drug reactions: inflammatory episodes as consequence and contributorChemico-Biological Interactions, 2004
- Captopril‐Induced Skin EruptionsThe Journal of Clinical Pharmacology, 1982